@article{2133504b4d99494a8a059f9586308002,
title = "Treatment of Immunoglobulin Light Chain Amyloidosis Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement",
abstract = "Immunoglobulin light chain amyloidosis (AL amyloidosis) has an incidence of approximately 1 case per 100,000 person-years in Western countries. The rarity of the condition not only poses a challenge for making a prompt diagnosis but also makes evidenced decision making about treatment even more challenging. Physicians caring for patients with AL amyloidosis have been borrowing and customizing the therapies used for patients with multiple myeloma with varying degrees of success. One of the biggest failings in the science of the treatment of AL amyloidosis is the paucity of prospective trials, especially phase 3 trials. Herein, we present an extensive review of the literature with an aim of making recommendations in the context of the best evidence and expert opinion.",
author = "Angela Dispenzieri and Francis Buadi and Kumar, {Shaji K.} and Reeder, {Craig B.} and Tamur Sher and Lacy, {Martha Q.} and Kyle, {Robert A.} and Mikhael, {Joseph R.} and Vivek Roy and Nelson Leung and Martha Grogan and Prashant Kapoor and Lust, {John A.} and David Dingli and Go, {Ronald S.} and Hwa, {Yi Lisa} and Hayman, {Suzanne R.} and Rafael Fonseca and Sikander Ailawadhi and Bergsagel, {P. Leif} and Ascher Chanan-Khan and Rajkumar, {S. Vincent} and Russell, {Stephen J.} and Keith Stewart and Zeldenrust, {Steven R.} and Gertz, {Morie A.}",
note = "Funding Information: Potential Competing Interests: Dr Dispenzieri has received research support from Celgene, Millenium, Pfizer, Jannsen, and Alnylam. Dr Kumar as received research support from Celgene, Novartis, Onyx, Millennium, Sanofi, and Janssen. Dr Reeder has received research support from Celgene, Novartis, and Millennium. Dr Mikhael has received research support from Celgene, Onyx, Abbvie, and Sanofi. Dr Grogan has received research support from Pfizer; and consulting fees from Prothena. Dr Fonseca has a patent for the prognostication of multiple myeloma based on genetic categorization of the disease; has received consulting fees from Celgene, Genzyme, BMS, Bayer, Lilly, Onyx, Binding Site, Novartis, Sanofi, Millennium, and AMGEN; has sponsored research from Onyx; and is a member of the scientific advisory board of Applied Biosciences. Dr Ailawadhi has received honoraria from Millennium and Amgen. Dr Bergsagel has received research support from Novartis and Constellation Pharmaceuticals; and consultant fees from Amgen, Janssen, Sanofi-Aventis, Mundipharma, and BMS. Dr Stewart has received research support from Celgene and Millennium Pharmaceuticals; and consulting fees from Novartis and Millennium Pharmaceuticals. Dr Gertz has received research support from ISIS and Prothena; and honoraria from Celgene, Millennium Pharmaceuticals, and Novartis. Funding Information: Grant Support: This work was supported in part by the Robert A. Kyle Hematologic Malignancies Program, the Jabbs Foundation, and the Predolin Foundation. Publisher Copyright: {\textcopyright} 2015 Mayo Foundation for Medical Education and Research.",
year = "2015",
month = aug,
day = "1",
doi = "10.1016/j.mayocp.2015.06.009",
language = "English (US)",
volume = "90",
pages = "1054--1081",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "8",
}